Another important finding is the observation that a large proportion of patients with HER2-positive BC develop resistance to trastuzumab and this might be due to the loss of expression of HER2 extracellular domain on tumor cells, caused by shedding/cleavage of HER2 by metalloproteinases [15]. The gene discussed is ERBB2; the disease is neoplasm.